三联药物治疗慢性自发性荨麻疹65例临床观察

发布时间：2018-04-15 17:15

本文选题：白芍总苷 + 组胺受体拮抗剂　；参考：《中国皮肤性病学杂志》2017年10期

【摘要】：目的评价三联药物方案治疗慢性自发性荨麻疹的临床疗效及安全性。方法将2014年4月-2016年4月本科诊治的130例慢性自发性荨麻疹患者采用随机数字表法分为两组,各65例。对照组予地氯雷他定联合左西替利嗪,治疗组予地氯雷他定联合左西替利嗪及白芍总苷,疗程均为8周。结果治疗组近期疗效显著优于对照组,治疗组患者风团持续时间显著短于对照组,治疗组患者治疗后UAS7评分显著低于对照组和其治疗前UAS7评分,治疗组患者复发率显著低于对照组,以上差异均有统计学意义(均P0.05)。但是两组患者不良反应发生率差异无统计学意义(P0.05)。结论三联药物治疗慢性自发性荨麻疹可有效缓解患者的临床症状和体征,降低远期复发风险,且安全性好。
[Abstract]:Objective to evaluate the efficacy and safety of triple drug regimen in the treatment of chronic spontaneous urticaria.Methods 130 patients with chronic spontaneous urticaria from April 2014 to April 2016 were randomly divided into two groups, 65 cases in each group.The control group received desloratadine combined with levo-cetirizine, the treatment group received desloratadine combined with levocetirizine and total glucoside of paeony for 8 weeks.Results the short-term curative effect of the treatment group was significantly better than that of the control group. The duration of wind mass in the treatment group was significantly shorter than that in the control group. The UAS7 score of the treatment group was significantly lower than that of the control group and its UAS7 score before treatment.The recurrence rate in the treatment group was significantly lower than that in the control group, and the difference was statistically significant (P 0.05).However, there was no significant difference in the incidence of adverse reactions between the two groups (P 0.05).Conclusion Triple drug therapy for chronic spontaneous urticaria can effectively relieve the clinical symptoms and signs, reduce the long-term risk of recurrence, and the safety is good.
【作者单位】：达州市中心医院皮肤科;
【分类号】：R758.24

【相似文献】